Validation of the Arabic version of the oral hypoglycemic agent questionnaire version 2 (OHA-Q ver. 2) in Tabuk, Saudi Arabia: A pilot study

Diabetes mellitus is common globally, and the Arab countries are no exception. Oral hypoglycemic agents are major pillars of diabetes management. The Oral Hypoglycemic Agent Questionnaire Version 2 (OHA-Q ver. 2) is unavailable in Arabic. Therefore, the study's goal was to validate the questionnaire for use among patients with diabetes in Saudi Arabia. Thirty patients with diabetes were randomly selected from those attending regular follow-ups at the King Fahd Specialist Hospital - Diabetes Center in Tabuk, Saudi Arabia. The study took place in March and April 2023. A structured questionnaire was utilized, incorporating sociodemographic data and the OHA-Q ver. 2. The questionnaire's validity and reliability were evaluated through forward and backward translation, expert review, and Cronbach's Alpha analysis. The results showed that a total of 30 diabetic patients participated in the questionnaire validation, with 60% being female, a mean age of 51.1 ± 14.056 years, and 94% diagnosed with type 2 diabetes. The internal consistency of the OHA-Q ver. 2 was highest for the "treatment convenience" subscale (0.83) and lowest for "satisfaction" (0.78). The overall content validity score was 0.875, and Cronbach’s Alpha for reliability was 0.88. The Arabic version of the OHA-Q ver. 2 has proven to be a valid and reliable tool for diabetic patients in Arab countries.